In this edition, FDA approves subcutaneous chemotherapy for solid tumors, improvements to shared decision-making and more.

Read the full coverage here:

FDA approves Hernexeos as first oral therapy for NSCLC with HER2 mutations

Communication, knowledge critical to improve shared decision-making for lung cancer

Detection of ctDNA could help determine use of immunotherapy for small cell lung cancer

Subcutaneous amivantamab plus lazertinib produces similar results to IV regimen in NSCLC

Lung cancer screening guidance needed for certain never-smokers

References:

Bi N, et al. Abstract 2034. Presented at IASLC World Conference on Lung Cancer; Sept. 6-9, 2025; Barcelona.

Press Release

Scott SC, et al. Abstract 1798. Presented at IASLC World Conference on Lung Cancer; Sept. 6-9, 2025; Barcelona.

Shum E, et al. Abstract 2172. Presented at IASLC World Conference on Lung Cancer; Sept. 6-9, 2025; Barcelona.

Villalon D, et al. Abstract 2368. Presented at IASLC World Conference on Lung Cancer; Sept. 6-9, 2025; Barcelona.